https://arolstar52-zhtest.hf.space/index.php?action=history&feed=atom&title=ADB-BUTINACA
ADB-BUTINACA - 版本历史
2026-07-15T09:27:37Z
在这个wiki上该页的修订历史
MediaWiki 1.43.9
https://arolstar52-zhtest.hf.space/index.php?title=ADB-BUTINACA&diff=4345763&oldid=prev
imported>Htmlzycq：/* top */
2026-03-18T01:00:52Z
<p><span class="autocomment">top</span></p>
<p><b>新页面</b></p><div>{{Infobox drug<br />
| IUPAC_name = ''N''-[(2''S'')-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-butyl-1''H''-indazole-3-carboxamide<br />
| image = ADB-BUTINACA_structure.png<br />
| drug_name = ADB-BUTINACA<br />
<br />
<!--Clinical data--><br />
| tradename = <br />
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --><br />
| pregnancy_US = <!-- A / B / C / D / X --><br />
| pregnancy_category = <br />
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --><br />
| legal_BR = F2<br />
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-15 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref><br />
| legal_CA = Schedule II<br />
| legal_DE = NpSG<br />
| legal_UK = Class B<br />
| legal_US = Schedule I<br />
| legal_status = <br />
| routes_of_administration =<br />
<br />
<!--Pharmacokinetic data--><br />
| bioavailability = <br />
| protein_bound = <br />
| metabolism = <br />
| elimination_half-life = <br />
| excretion =<br />
<br />
<!--Identifiers--><br />
| CAS_number_Ref = {{cascite|correct|??}}<br />
| CAS_number = 2682867-55-4<br />
| UNII_Ref = {{fdacite|correct|FDA}}<br />
| UNII = ZJ6LS4NVM9<br />
| ATC_prefix = <br />
| ATC_suffix = <br />
| PubChem = 155907792<br />
| ChemSpiderID = 81407832<br />
| ChEMBL = 5169682<br />
| smiles = O=C(N[C@H](C(N)=O)C(C)(C)C)C1=NN(CCCC)C2=C1C=CC=C2<br />
| StdInChI = 1S/C18H26N4O2/c1-5-6-11-22-13-10-8-7-9-12(13)14(21-22)17(24)20-15(16(19)23)18(2,3)4/h7-10,15H,5-6,11H2,1-4H3,(H2,19,23)(H,20,24)/t15-/m1/s1<br />
| StdInChIKey = GPWADXHYJAZPAX-OAHLLOKOSA-N<br />
<br />
<!--Chemical data--><br />
| C=18 | H=26 | N=4 | O=2<br />
}}<br />
'''{{PAGENAME}}'''是一种含氮[[有机化合物]]，分子式[[C18H26N4O2|C<sub>18</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>]]，属于[[合成大麻素]]，与[[AB-PINACA]]结构类似，其中[[异丙基]]变为[[叔丁基]]，[[正戊基]]变为[[正丁基]]<ref>{{cite journal | vauthors = Kavanagh P, Pechnikov A, Nikolaev I, Dowling G, Kolosova M, Grigoryev A | title = Detection of ADB-BUTINACA Metabolites in Human Urine, Blood, Kidney and Liver | journal = Journal of Analytical Toxicology | volume = 46 | issue = 6 | pages = 641–650 | date = July 2022 | pmid = 34341821 | doi = 10.1093/jat/bkab088 }}</ref><ref>{{cite journal | vauthors = Sia CH, Wang Z, Goh EM, Tan YL, Fong CY, Moy HY, Chan EC | title = Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse | journal = Clinical Chemistry | volume = 67 | issue = 11 | pages = 1534–1544 | date = November 2021 | pmid = 34387654 | doi = 10.1093/clinchem/hvab134 | doi-access = free }}</ref>。它可以通过[[氣相色譜法-質譜聯用#GC-串聯MS|GC−MS/MS]]进行检测<ref>Wang, Y., Pan, Y., Yang, H. et al. Quantification of MDMB-4en-PINACA and ADB-BUTINACA in human hair by gas chromatography–tandem mass spectrometry. Forensic Toxicol., 2022. 40, 340–348. {{doi|10.1007/s11419-022-00615-z}}.</ref>。<br />
<br />
==参考文献==<br />
{{reflist}}<br />
<br />
==外部链接==<br />
{{大麻素}}<br />
<br />
[[Category:大麻素]]<br />
[[Category:策划药]]<br />
[[Category:吲唑甲酰胺]]<br />
[[Category:叔丁基化合物]]<br />
[[Category:正丁基化合物]]</div>
imported>Htmlzycq